Terms: = Pancreatic cancer AND CCND1, BCL1, 595, ENSG00000110092, PRAD1, U21B31, D11S287E
123 results:
1. Glucagon-Like Peptide-1 Receptor Agonists and pancreatic cancer Risk in Patients With Type 2 Diabetes.
Dankner R; Murad H; Agay N; Olmer L; Freedman LS
JAMA Netw Open; 2024 Jan; 7(1):e2350408. PubMed ID: 38175642
[TBL] [Abstract] [Full Text] [Related]
2. The impact of surgical-oncologic textbook outcome in patients with stage I to III pancreatic ductal adenocarcinoma: A cross-validation study of two national registries.
Petruch N; Servin Rojas M; Lillemoe KD; Castillo CF; Braun R; Honselmann KC; Lapshyn H; Deichmann S; Abdalla TSA; Hummel R; Klinkhammer-Schalke M; Tol KK; Zeissig SR; Keck T; Wellner UF; Qadan M; Bolm L
Surgery; 2024 Apr; 175(4):1120-1127. PubMed ID: 38092633
[TBL] [Abstract] [Full Text] [Related]
3. CENPA functions as a transcriptional regulator to promote hepatocellular carcinoma progression via cooperating with YY1.
Liao J; Chen Z; Chang R; Yuan T; Li G; Zhu C; Wen J; Wei Y; Huang Z; Ding Z; Chu L; Liang J; Zhang B
Int J Biol Sci; 2023; 19(16):5218-5232. PubMed ID: 37928273
[TBL] [Abstract] [Full Text] [Related]
4. A multicenter validation study for determining the condition of nonanatomical or minor anatomical hepatectomies satisfying technical difficulty of current high-level hepatectomy certificated by the Japanese Society of Hepato-Biliary-pancreatic Surgery.
Matsuki R; Sakamoto Y; Yoshida M; Ogiso S; Soyama A; Seki Y; Tokumitsu Y; Eguchi S; Hasegawa K; Nagano H; Kokudo N; Hatano E
J Hepatobiliary Pancreat Sci; 2023 Nov; 30(11):1218-1226. PubMed ID: 37798934
[TBL] [Abstract] [Full Text] [Related]
5. Long noncoding RNA CASC9 promotes pancreatic cancer progression by acting as a ceRNA of miR-497-5p to upregulate expression of ccnd1.
Zhou J; Song G; Su M; Zhang H; Yang T; Song Z
Environ Toxicol; 2023 Jun; 38(6):1251-1264. PubMed ID: 36947456
[TBL] [Abstract] [Full Text] [Related]
6. Splenectomy and azygoportal disconnection decreases the risk of hepatocellular carcinoma for cirrhosis patients with portal hypertension bleeding: a 10-year retrospective follow-up study based on the inverse probability of treatment weighting method.
Gao TM; Zhou J; Xiang XX; Jin SJ; Qian JJ; Zhang C; Zhou BH; Tang H; Bai DS; Jiang GQ
J Gastroenterol; 2023 May; 58(5):503-512. PubMed ID: 36943530
[TBL] [Abstract] [Full Text] [Related]
7. Integrated Genomic and Clinicopathologic Approach Distinguishes pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract] [Full Text] [Related]
8. Differentially Expressed Cell Cycle Genes and STAT1/3-Driven Multiple cancer Entanglement in Psoriasis, Coupled with Other Comorbidities.
Dorai S; Alex Anand D
Cells; 2022 Nov; 11(23):. PubMed ID: 36497125
[TBL] [Abstract] [Full Text] [Related]
9. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA.
Wu H; Guo S; Liu X; Li Y; Su Z; He Q; Liu X; Zhang Z; Yu L; Shi X; Gao S; Wang H; Pan Y; Ma C; Liu R; Dai M; Jin G; Liang Z
BMC Med; 2022 Nov; 20(1):458. PubMed ID: 36434648
[TBL] [Abstract] [Full Text] [Related]
10. Silencing of KNTC1 inhibits hepatocellular carcinoma cells progression via suppressing PI3K/Akt pathway.
Tong H; Liu X; Peng C; Shen B; Zhu Z
Cell Signal; 2023 Jan; 101():110498. PubMed ID: 36273753
[TBL] [Abstract] [Full Text] [Related]
11. Prevalence, features, and explanations of missed and misinterpreted pancreatic cancer on imaging: a matched case-control study.
Hoogenboom SA; Engels MML; Chuprin AV; van Hooft JE; LeGout JD; Wallace MB; Bolan CW
Abdom Radiol (NY); 2022 Dec; 47(12):4160-4172. PubMed ID: 36127473
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic Factors of Small Non-Functional pancreatic Neuroendocrine Tumors and the Risk of Lymph Node Metastasis: A Population-Level Study.
Tan Q; Wang X; Li Y; Liu Y; Liu X; Ke N
Front Endocrinol (Lausanne); 2022; 13():907415. PubMed ID: 35873006
[TBL] [Abstract] [Full Text] [Related]
13. Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors.
Poorebrahim M; Abazari MF; Moradi L; Shahbazi B; Mahmoudi R; Kalhor H; Askari H; Teimoori-Toolabi L
PLoS Comput Biol; 2022 Apr; 18(4):e1009962. PubMed ID: 35472201
[TBL] [Abstract] [Full Text] [Related]
14. Molecular Characterization of KRAS Wild-type Tumors in Patients with pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract] [Full Text] [Related]
15. Contemporary outcomes of pancreaticoduodenectomy for benign and precancerous cystic lesions.
Aizpuru M; Starlinger P; Nagorney DM; Smoot RL; Truty MJ; Kendrick ML; Cleary SP
HPB (Oxford); 2022 Sep; 24(9):1416-1424. PubMed ID: 35140056
[TBL] [Abstract] [Full Text] [Related]
16. A novel long non-coding RNA regulates the integrin, ITGA2 in breast cancer.
Verhoeff TJ; Holloway AF; Dickinson JL
Breast Cancer Res Treat; 2022 Feb; 192(1):89-100. PubMed ID: 35098437
[TBL] [Abstract] [Full Text] [Related]
17. MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis.
Du L; Wang D; Wei X; Liu C; Xiao Z; Qian W; Song Y; Hou X
BMC Gastroenterol; 2022 Jan; 22(1):29. PubMed ID: 35062876
[TBL] [Abstract] [Full Text] [Related]
18. Reconstruction and Exploratory Analysis of mTORC1 Signaling Pathway and Its Applications to Various Diseases Using Network-Based Approach.
Buddham R; Chauhan S; Narad P; Mathur P
J Microbiol Biotechnol; 2022 Mar; 32(3):365-377. PubMed ID: 35001007
[TBL] [Abstract] [Full Text] [Related]
19. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy.
Shen J; Qi W; Dai J; Leng S; Jiang K; Zhang Y; Ran S; Li C; Wen T
Chin Med J (Engl); 2021 Dec; 135(3):301-308. PubMed ID: 34958539
[TBL] [Abstract] [Full Text] [Related]
20. FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.
Wu SQ; Huang SH; Lin QW; Tang YX; Huang L; Xu YG; Wang SP
Pharmacol Res; 2022 Jan; 175():106040. PubMed ID: 34954029
[TBL] [Abstract] [Full Text] [Related]
[Next]
